- $2.05bn
- $1.53bn
- $6.94m
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Immunome climbs as Stifel initiates coverage
Immunome, Inc. reports results for the quarter ended June 30 - Earnings Summary
Oncology firm Immunome's Q2 net loss widens as R&D costs rise
Immunome, Inc. expected to post a loss of 52 cents a share - Earnings Preview
Brief: Immunome Says Varegacestat Treatment Resulted In Statistically Significant Improvements In Primary And All Key Secondary Efficacy Endpoints
Immunome's Q1 net loss widens on higher expenses
Brief: Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Immunome reports net loss for 2025
Brief: Immunome Reports Inducement Grants Under Nasdaq Listing Rule
U.S. STOCKS ON THE MOVE-Robinhood Markets, Cannabis stocks, Hyatt Hotels
U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
Immunome slips after $400 mln stock sale
Brief: Immunome Announces Pricing Of Public Offering Of 18,625,000 Shares At $21.50 Each
Advisory: Alert from Equity-Insider.com was published in error and has been withdrawn
Immunome dips after launching $400 mln stock offering